Germany is the largest economy in Europe and known worldwide for its highly productive manufacturing sector. Significant investments in new technologies and renewable energies are driving its next phase of growth. With over 500 consultants at our offices in Berlin, Hamburg, Munich, Duesseldorf and Frankfurt, we are present in all economic centres in Germany.
Our excellent lawyers are ranked in the top tier in the major legal directories in 17 sectors - including technology, life sciences and healthcare, renewable energies, finance and insurance, and real estate. We work closely with our international colleagues in Europe, Asia and North America to successfully navigate our clients through complex cross-border transactions and ever-changing regulatory challenges, and to protect them from far-reaching disputes.
Doing Business and Investing in Germany: A guide to help foreign investors
Offices
With over 350 consultants in our offices in Berlin, Hamburg, Munich, Düsseldorf and Frankfurt, we are present in all economic centres in Germany.
Latest news & insights
Hamburg Regional Court: validity of the presumption of availability in maintenance contracts
#7: State of the EU Crypto Industry: MiCA, Tokenisation and What Comes Next
Online coaching and distance learning: Federal Court of Justice clarifies application of the Distance Learning Protection Act
Impact of the new Biotech Act on Clinical Trials in the EU
A European Perspective #1 | EU Biotech Act: Faster Clinical Trial Approvals Ahead | The European Commission’s proposed Biotech Act aims to streamline clinical trial procedures, shorten approval timelines, and harmonise data protection rules across the EU. If adopted, the reform could significantly accelerate multinational clinical research in the EU.
4 of 9 Insights
The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU
A European Perspective #1 | The EU’s largest pharmaceutical law reform in over 20 years introduces a new regulatory exclusivity framework, revised orphan drug incentives and an antimicrobial voucher. Strategic exclusivity planning will become essential for pharmaceutical companies.
1 of 9 Insights
Online
In Person